Brief: Rani Therapeutics Reports First Quarter 2023 Financial Results

Rani Therapeutics Holdings

10/05/2023 21:18

May 10 (Reuters) - Rani Therapeutics Holdings Inc
 RANI.O :
    * RANI THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS;
PROVIDES CORPORATE UPDATE
    * RECEIVED PRELIMINARY FEEDBACK FROM FDA ON RT-102
DEVELOPMENT
PLANS; 505(B)(2) PATHWAY FOR RT-102 COULD BE SUITABLE
    * INITIATION OF PHASE 2 CLINICAL TRIAL FOR RT-102 FOR
TREATMENT OF
OSTEOPOROSIS EXPECTED IN 2H OF 2023
    * RANI THERAPEUTICS - ANNOUNCED PARTNERSHIP WITH CELLTRION
ON
DEVELOPMENT OF RT-111
    * RANI THERAPEUTICS - CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES AS OF MARCH 31, 2023 TOTALED $86.8 MILLION
    * RANI THERAPEUTICS HOLDINGS - EXPECTS ITS CASH, CASH
EQUIVALENTS
AND MARKETABLE SECURITIES TO BE SUFFICIENT TO FUND ITS
OPERATIONS TO MID-2024
    * QTRLY LOSS PER SHARE $0.33
    * Q1 EARNINGS PER SHARE VIEW $-0.41 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX8PfxKG 
Further company coverage:  RANI.O 

 ((Reuters.Briefs@thomsonreuters.com;))